Table 2. Diagnostic performance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial cytology-proven nodal disease at presentation.

Findings of SLN	No. (%)
SLN identification rate after NAC	115/120 (95.8)
No. of nodes retrieved*	3 (1-7)
No residual axillary metastases (ypN0)	18/89 (20.2)
Residual axillary metastases	71/89 (79.8)
Residual metastases limited to SLNs	27/70 (38.6)
Falsely negative SLNs	2/20 (10.0)

SLN=sentinel lymph node; NAC=neoadjuvant chemotherapy.

^*Median (range).